Want to see ICLR full AI Analyst Report?
ICLR Stock Chart & Stats
$170.02
$1.29(0.78%)
At close: 4:00 PM EDT
$170.02
$1.29(0.78%)
Day’s Range― - ―
52-Week Range$66.57 - $203.91
Previous CloseN/A
Volume71.62K
Average Volume (3M)986.74K
Market Cap
$13.44B
Enterprise Value$16.04B
Total Cash (Recent Filing)$928.38M
Total Debt (Recent Filing)$3.49B
Price to Earnings (P/E)43.2
Beta0.96
Next Earnings
Oct 27, 2026EPS Estimate
2.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.29
Shares Outstanding77,154,205
10 Day Avg. Volume803,869
30 Day Avg. Volume986,735
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)1.55
Price to Sales (P/S)1.73
P/FCF Ratio16.58
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue1.94
Enterprise Value/Gross Profit8.89
Enterprise Value/Ebitda12.88
Forecast
1Y Price Target
$188.25Price Target Upside10.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)10.56
Revenue Forecast (FY)$8.14B
Bulls Say, Bears Say
Bulls Say
Strong BookingsStrong bookings and a book-to-bill ratio above one indicate demand is replenishing delivered work and supporting future revenue visibility. Broad awards across large pharma, biotech, and mid-size customers also strengthen diversification and reduce reliance on any single sponsor segment.
Cash GenerationRobust operating and free cash flow gives ICON internal funding for technology investment, debt management, and other capital priorities. Strong conversion of reported earnings into cash can improve resilience through uneven demand and provide flexibility without depending solely on external financing.
Technology PlatformInvestment in AI-enabled delivery tools can improve productivity and deepen ICON’s technology-enabled CRO offering over time. Orbis, Meridian, and workflow automation may strengthen differentiation, help scale complex trials, and support more efficient service delivery across its global platform.
Bears Say
Margin CompressionThe sharp year-over-year margin decline indicates that profitability is not yet stable despite ICON’s scale and cash generation. Persistent pass-through activity, mix effects, or cost pressure could limit operating leverage and reduce the earnings benefit of future revenue growth.
Direct Fee DeclineA projected decline in underlying direct fees points to pressure in the core service base rather than merely a temporary accounting effect. The Symphony divestiture adds a further comparison headwind, making near-term revenue expansion and recovery in organic earnings more difficult.
Demand VolatilityUneven demand across customer groups and service lines can make staffing, capacity planning, and revenue conversion less predictable. Moderating large-pharma RFP activity and variable early-stage demand may create pauses between bookings and execution, complicating sustained growth.
ICLR FAQ
What was Icon plc’s price range in the past 12 months?
Icon plc lowest stock price was $66.57 and its highest was $203.91 in the past 12 months.
What is Icon plc’s market cap?
Icon plc’s market cap is $13.44B.
When is Icon plc’s upcoming earnings report date?
Icon plc’s upcoming earnings report date is Oct 27, 2026 which is in 5 days.
How were Icon plc’s earnings last quarter?
Icon plc released its earnings results on Jul 29, 2026. The company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.545 by $0.015.
Is Icon plc overvalued?
According to Wall Street analysts Icon plc’s price is currently Undervalued.
Does Icon plc pay dividends?
Icon plc does not currently pay dividends.
What is Icon plc’s EPS estimate?
Icon plc’s EPS estimate is 2.62.
How many shares outstanding does Icon plc have?
Icon plc has 77,154,205 shares outstanding.
What happened to Icon plc’s price movement after its last earnings report?
Icon plc reported an EPS of $2.56 in its last earnings report, beating expectations of $2.545. Following the earnings report the stock price went down -7.1%.
Which hedge fund is a major shareholder of Icon plc?
Currently, no hedge funds are holding shares in ICLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Icon Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$188.25 (10.72% Upside)
$188.25 (10.72% Upside)
Blogger Sentiment
Bullish
ICLR Sentiment 80%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 292.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.6%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.14%
12-Months-Change
Fundamentals
Return on Equity
3.54%
Trailing 12-Months
Asset Growth
-0.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Icon plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
ICLR Company Deck
ICLR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly constructive. ICON reported strong bookings, improving demand indicators, sequential EBITDA and margin progression, reaffirmed full-year guidance, solid cash generation, progress in biotech and China, and continued investment in AI and growth capabilities. These positives were tempered by lower year-over-year gross margin and adjusted EBITDA, elevated pass-through activity, a projected direct fee decline, nonrecurring Q2 SG&A benefits, large pharma RFP moderation, and a Symphony-related revenue drag. Overall, the positive operating and commercial trends significantly outweighed the stated challenges.View all ICLR earnings summariesICLR Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$188.25
▲(10.72% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Charles River Labs
―
Labcorp Holdings
―
Thermo Fisher
―
IQVIA Holdings
―
Medpace Holdings
―
Ownership Overview
0.07% Insiders
36.67% Mutual Funds
5.65% Other Institutional Investors
53.73% Public Companies and
Individual Investors










